These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 2592579)

  • 1. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new drug approvals of 1987, 1988, and 1989: trends in drug development.
    Kaitin KI; DiCerbo PA; Lasagna L
    J Clin Pharmacol; 1991 Feb; 31(2):116-22. PubMed ID: 2010558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in drug development: the 1985-86 new drug approvals.
    Kaitin KI; Richard BW; Lasagna L
    J Clin Pharmacol; 1987 Aug; 27(8):542-8. PubMed ID: 3655005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate the availability of important new drugs.
    Kaitin KI; Phelan NR; Raiford D; Morris B
    J Clin Pharmacol; 1991 Jan; 31(1):17-24. PubMed ID: 2045524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
    Rising K; Bacchetti P; Bero L
    PLoS Med; 2008 Nov; 5(11):e217; discussion e217. PubMed ID: 19067477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rate of development of new drugs in the United States, 1963 through 1975.
    Wardell WM; Hassar M; Anavekar SN; Lasagna L
    Clin Pharmacol Ther; 1978 Aug; 24(2):133-45. PubMed ID: 679593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration.
    Novack GD
    Am J Ophthalmol; 1998 Jul; 126(1):122-6. PubMed ID: 9683158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.
    Zhang AD; Schwartz JL; Ross JS
    Milbank Q; 2019 Sep; 97(3):796-819. PubMed ID: 31304643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From idea to market: the drug approval process.
    Lipsky MS; Sharp LK
    J Am Board Fam Pract; 2001; 14(5):362-7. PubMed ID: 11572541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
    Choi H; Lee H; Park B; Kim C; Lee J
    Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
    Camp JR; Fuhs JV; Beattie SD; Asay RL; Hoffman RD
    Ther Innov Regul Sci; 2021 May; 55(3):568-582. PubMed ID: 33492633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.